How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML).

Research output: Contribution to journal › Article › peer-review

Authors

Colleges, School and Institutes

Details

Original languageEnglish
JournalBritish Journal of Haematology
Publication statusE-pub ahead of print - Oct 2020
Save citation Saved citations (0)

Copy the text from this field...

View graph of relations

DOI

By the same authors

Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.

Sylvie Freeman, Oct 2020, In : JAMA Oncology.

Research output: Contribution to journal › Article › peer-review

Less is not necessarily more: toward a rational selection of the conditioning regimen in acute myeloid leukemia

Sylvie Freeman, 20 Apr 2020, In : Journal of Clinical Oncology . 38, 12, p. 1249-1251 3 p.

Research output: Contribution to journal › Editorial

Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting

Sylvie Freeman & 4 others, , 2 Apr 2020, In : British Journal of Haematology.

Research output: Contribution to journal › Article › peer-review